Close

move up move left move right move bottom

Share the News About XARELTO®

Want to share this page with a colleague?

By selecting SEND, you are requesting that we contact on your behalf the person that you specify here. The names and e-mail addresses that you provide for you and your colleague are required, but they will not be used other than to distribute the communication you request. Our Privacy Policy governs the use of the information you provide.

*Required field.

To:

From:

 

Indications

 

IMPORTANT SAFETY INFORMATION

 

Indication and Important saftey Information

 

  • Reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). There are limited data on the relative effectiveness of XARELTO® (rivaroxaban) and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled.
  • Treatment of deep vein thrombosis (DVT).
  • Treatment of pulmonary embolism (PE).
  • Reduction in the risk of recurrence of DVT and of PE following initial 6 months treatment for DVT and/or PE.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing knee replacement surgery.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing hip replacement surgery.